JPIAMR 14th Call Partner Search Tool

General Information

• Project title: Anti-virulence agent F19 combats MRSA and other Gram-positive infections
• Type: Project looking for partner
• Organisation: Q2Pharma
• Country: Israel (IL)

Research area

• Scientific area(s) of the call:
  1. Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines)
• One Health Setting:

  Human Health

• Type of studies/experimental approaches:

  preclinical and clinical studies in human and in all veterinary settings

• Keywords:

  anti-virulence;small molecule; potentiation of antibiotic efficacy; MRSA;biofilm inhibition

• Brief description of your expertise / expertise you are looking for:

  Q2Pharma is looking for partners with expertise in medicinal chemistry, animal experiments, regulatory expertise, toxicity trials

• Brief description of your project / the project you would like to join:

  F19 is a small-molecule drug that disarms the pathogen of disease-causing toxins. It binds to a staphylococcal transcription factor, thereby preventing its association with DNA. The result is blockage of transcription of a series of toxins. Efficacy has been established against MRSA, Staph epidermidis, Streptococcus pyogens and Streptococcus pneumoniae. F19 is developed for oral, parenteral and topical application. We are about half way through the preclinical stage. In vivo efficacy and toxicity data are available, as well as PK data. In addition to toxin inhibition F19 also potentiates the efficacy of conventional antibiotics in combination therapy. This property allows the reintroduction of obsolete antibiotics into the clinic. Additionally, F19 inhibits biofilm formation.

Menachem Shoham

• Organisation: Q2Pharma
• Position: Co-Founder and Chief Scientific Officer
• E-mail: menachem@q2pharma.com
• Phone: +972-525984109
• Web: www.q2pharma.com